Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Omentin associates with serum metabolite profiles indicating lower diabetes risk: KORA F4 Study

Ratter-Rieck JM., Shi M., Suhre K., Prehn C., Adamski J., Rathmann W.

Prospective Study with a reported sample of 1124 on Type 2 Diabetes, Cardiovascular Disease, Stroke Research, Chronic Inflammation, published in BMJ Open Diabetes Res Care (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
BMJ Open Diabetes Res Care (2024)
Reported sample size
1124
Source database
Europe PMC
PMID
38442989
PMCID
PMC11148672
DOI
10.1136/bmjdrc-2023-003865
Citations
2

Abstract (original English)

Introduction Circulating omentin levels have been positively associated with insulin sensitivity. Although a role for adiponectin in this relationship has been suggested, underlying mechanisms remain elusive. In order to reveal the relationship between omentin and systemic metabolism, this study aimed to investigate associations of serum concentrations of omentin and metabolites. Research design and methods This study is based on 1124 participants aged 61-82 years from the population-based KORA (Cooperative Health Research in the Region of Augsburg) F4 Study, for whom both serum omentin levels and metabolite concentration profiles were available. Associations were assessed with five multivariable regression models, which were stepwise adjusted for multiple potential confounders, including age, sex, body mass index, waist-to-hip ratio, lifestyle markers (physical activity, smoking behavior and alcohol consumption), serum adiponectin levels, high-density lipoprotein cholesterol, use of lipid-lowering or anti-inflammatory medication, history of myocardial infarction and stroke, homeostasis model assessment 2 of insulin resistance, diabetes status, and use of oral glucose-lowering medication and insulin. Results Omentin levels significantly associated with multiple metabolites including amino acids, acylcarnitines, and lipids (eg, sphingomyelins and phosphatidylcholines (PCs)). Pos

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansDiabetes MellitusInsulin ResistanceInsulinLectinsCytokinesAdiponectinGPI-Linked Proteins

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research